FluoGuide A/S Publishes Interim Report For Q4 2025

February 25, 2026 1:20 AM

Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report is available as attached document to this press release and on FluoGuide's website."In 2025, FluoGuide achieved several defining milestones that significantly advanced FG001 toward late-stage clinical development and established a clear regulatory pathway toward U.S. approval. The positive clinical...

Read more

Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update

February 24, 2026 4:15 PM

Regentis Biomaterials Ltd. ("Regentis" or the "Company"), a regenerative medicine company focused on innovative tissue repair solutions, today reported financial results for the year ended December 31, 2025 and provided an update on corporate and clinical developments."2025 was a transformational year for Regentis, marked by our successful IPO and a strengthened balance sheet with more than $7 million in cash, positioning us to potentially...

Read more

Bakar Labs Helps Companies Raise More Than $1 Billion in Its First Four Years of Operation

February 24, 2026 11:05 AM

Bakar Labs, UC Berkeley's flagship incubator supporting innovation in life sciences, energy and materials, today announced that its companies have raised more than $1 billion in cumulative funding over its first four years of operation. This underscores both the quality of its science and the resilience of its entrepreneurial ecosystem during a period of time when early-stage biotech funding sharply declined. Since its official opening in...

Read more

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

February 24, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Ascendiant Capital Markets has issued an updated equity research report covering the Company. According to the Ascendiant Capital Markets, the report raises its price target to $5.00 per share. All statements, opinions, estimates, projections, and conclusions contained in analyst reports represents the views of the respective analysts and are not those of IGC...

Read more

Microbix Announces Issuance of Stock Options

February 24, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces the issuance of stock options under its shareholder-approved stock option plan (the "Stock Option Plan"), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.Details of the Option IssuanceIn consultation with management, Microbix's Board of Directors has approved...

Read more

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

February 23, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced the addition of Visionary Investigators Network ("VIN") as a clinical research site participating in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease dementia. VIN operates clinical research programs embedded within established private neurology practices, providing access to well-characterized...

Read more

Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus

February 23, 2026 7:00 AM

Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu. The collaboration follows a previously announced Non-Disclosure...

Read more

BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting

February 23, 2026 4:15 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced the nomination of. Kate Hermans and Scott Zinober as new members of the Board of Directors. Their elections will be put forward for shareholder approval at the Annual General Meeting (AGM) on April 29, 2026. While...

Read more

Faron's Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026

February 23, 2026 2:20 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that data from its Phase I/II BEXMAB trial evaluating bexmarilimab in combination with azacitidine for the treatment of higher-risk myelodysplastic syndromes (MDS) have been accepted for presentation at the 66th Annual Scientific Meeting of the British Society for Haematology...

Read more

FDA Clears FluoGuide's IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track

February 20, 2026 3:00 PM

FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces that the U.S. Food and Drug Administration (FDA) has informed the Company that it can proceed with the proposed clinical investigation for FG001. The IND supports the initiation of the Company's first trial supporting registration in patients with high-grade glioma (HGG).The IND submission...

Read more

Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair

February 19, 2026 8:30 AM

Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as Chief Medical Officer (CMO). Dr. Reske brings extensive experience in clinical development, regulatory strategy, and global clinical operations across the United States, Europe, and Israel, with a particular focus on cartilage...

Read more

Invitation to FluoGuide A/S (Nasdaq:FLUO) Live Webcast on 25 February 2026

February 19, 2026 3:30 AM

FluoGuide A/S (STO:FLUO) will publish its Annual Report 2025 on Wednesday, 25 February 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company's 2025 financial results, strategic progress and expectations for 2026 in a live webcast. The webcast is hosted by BioStock. The presentation will be followed by a live Q&A session, where questions can be asked during the event or submitted in advance by e-mail to...

Read more

Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML

February 19, 2026 2:30 AM

Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces a significant expansion of its clinical development program with the upcoming initiation of the Phase II BEAM-X Investigator-Initiated Trial (IIT) led by the Nordic AML Group with Dr. Mika Kontro serving as principal investigator. The trial evaluates...

Read more

Vicore Pharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026 2:15 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference:Location: VirtualFormat: Presentation and 1×1 meetingsPresentation Date and Time: Wednesday, February 25 at 4:00 PM ESTWebcast: LinkParticipants: Ahmed Mousa, CEO, and Megan...

Read more

Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs

February 17, 2026 8:30 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company"), a regenerative medicine company focused on innovative tissue repair solutions, today announced the expansion of its European clinical site network into new countries, strengthening its infrastructure to support both ongoing clinical programs including its pivotal Phase III U.S. Food and Drug Administration study and the Company's commercial strategy in Europe where GelrinC® has already...

Read more

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

February 17, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that the Canadian Intellectual Property Office ("CIPO") has issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company's Phase 2 clinical stage program for agitation associated with Alzheimer's disease. With this allowance, patent No. 3,095,729, titled "Method and Composition for Treating CNS Disorders", IGC has secured...

Read more

Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement

February 17, 2026 8:00 AM

Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD ("Khoury Medical"), a company focused on the development and commercialization of plant-derived dietary supplements. Under...

Read more

NAYA Therapeutics Appoints Jason D. Hurt, MD, MBA as Chief Medical Officer

February 17, 2026 7:45 AM

NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of astatine-211 (²¹¹At) targeted alpha therapies and natural killer (NK) cell engaging bifunctional antibodies, today announced that it has appointed Dr. Jason D. Hurt as its Chief Medical Officer."I'm excited to join NAYA at a key inflection point as they bring their highly-promising astatine-211...

Read more

Nature Cell (Chairman Jeong-Chan Ra) Signs Scientific Advisory Agreement with 2019 Nobel Laureate Professor Gregg L. Semenza of Johns Hopkins University

February 13, 2026 8:00 AM

Nature Cell, led by Chairman Jeong-Chan Ra and specializing in adult stem cell biotechnology, announced that its U.S. subsidiary, Nature Cell America Inc., has entered into a Scientific Advisory Agreement with Professor Gregg L. Semenza of Johns Hopkins University School of Medicine, recipient of the 2019 Nobel Prize in Physiology or Medicine.Professor Semenza was awarded the Nobel Prize for his groundbreaking research on how cells respond and...

Read more

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

February 12, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET. IGC Pharma's management will discuss recent clinical progress in its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease, including enrollment momentum and...

Read more